Ketesse (Dexketoprofen)

Dexketoprofen blocks cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which reduces the synthesis of prostaglandins—key mediators of pain, fever and inflammation. By lowering prostaglandin levels, the drug diminishes peripheral sensitisation of pain receptors and curtails the inflammatory response.

The appropriate dose of Ketesse is determined by the prescribing clinician based on the patient’s condition, weight, severity of pain and route of administration. Dosage regimens are individualized and should follow the prescriber’s instructions and local regulatory guidelines.

Safety data for dexketoprofen in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and only under medical supervision. Breastfeeding mothers should consult their healthcare provider before use.

To request Ketesse, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Dexketoprofen is the S‑enantiomer of ketoprofen, offering a faster onset of analgesia and potentially lower gastrointestinal side‑effects compared with racemic ketoprofen. Compared with ibuprofen or diclofenac, it provides comparable pain relief but may be preferred when rapid intravenous or intramuscular action is needed.

Ketesse should be stored at ambient temperature, below 25 °C, in its original container. Protect the product from moisture, direct sunlight and extreme temperature fluctuations to maintain stability and potency.

Ketesse is supplied as a sterile injectable solution for intramuscular or intravenous injection. Administration is performed by a qualified healthcare professional using aseptic technique, with the dose and route selected according to the clinical situation.

Serious risks include gastrointestinal bleeding, severe allergic reactions (anaphylaxis), renal impairment, hepatic dysfunction and cardiovascular events such as myocardial infarction or stroke. Patients should be monitored for signs of these conditions, and therapy should be discontinued if they occur.

Ketesse is contraindicated in patients with known hypersensitivity to dexketoprofen or other NSAIDs, active gastrointestinal ulceration or bleeding, severe renal or hepatic failure, and in those who have experienced a recent coronary artery bypass graft. Caution is also advised for patients with uncontrolled hypertension or heart failure.